336 related articles for article (PubMed ID: 18261682)
1. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies.
van der Steeg WA; Holme I; Boekholdt SM; Larsen ML; Lindahl C; Stroes ES; Tikkanen MJ; Wareham NJ; Faergeman O; Olsson AG; Pedersen TR; Khaw KT; Kastelein JJ
J Am Coll Cardiol; 2008 Feb; 51(6):634-42. PubMed ID: 18261682
[TBL] [Abstract][Full Text] [Related]
2. Association of High-Density Lipoprotein-Cholesterol Versus Apolipoprotein A-I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer-Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study.
van Capelleveen JC; Bochem AE; Boekholdt SM; Mora S; Hoogeveen RC; Ballantyne CM; Ridker PM; Sun W; Barter PJ; Tall AR; Zwinderman AH; Kastelein JJP; Wareham NJ; Khaw KT; Hovingh GK
J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28775061
[TBL] [Abstract][Full Text] [Related]
3. Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis.
Boekholdt SM; Arsenault BJ; Hovingh GK; Mora S; Pedersen TR; Larosa JC; Welch KM; Amarenco P; Demicco DA; Tonkin AM; Sullivan DR; Kirby A; Colhoun HM; Hitman GA; Betteridge DJ; Durrington PN; Clearfield MB; Downs JR; Gotto AM; Ridker PM; Kastelein JJ
Circulation; 2013 Oct; 128(14):1504-12. PubMed ID: 23965489
[TBL] [Abstract][Full Text] [Related]
4. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy.
Mora S; Glynn RJ; Ridker PM
Circulation; 2013 Sep; 128(11):1189-97. PubMed ID: 24002795
[TBL] [Abstract][Full Text] [Related]
5. Age, Sex, and Cardiovascular Risk Attributable to Lipoprotein Cholesterol Among Chinese Individuals with Coronary Artery Disease: A Case-Control Study.
Wu TT; Zheng YY; Yang YN; Li XM; Ma YT; Xie X
Metab Syndr Relat Disord; 2019 May; 17(4):223-231. PubMed ID: 30720383
[No Abstract] [Full Text] [Related]
6. High-density lipoprotein particle size and concentration and coronary risk.
El Harchaoui K; Arsenault BJ; Franssen R; Després JP; Hovingh GK; Stroes ES; Otvos JD; Wareham NJ; Kastelein JJ; Khaw KT; Boekholdt SM
Ann Intern Med; 2009 Jan; 150(2):84-93. PubMed ID: 19153411
[TBL] [Abstract][Full Text] [Related]
7. Congestive heart failure is associated with lipoprotein components in statin-treated patients with coronary heart disease Insights from the Incremental Decrease in End points Through Aggressive Lipid Lowering Trial (IDEAL).
Holme I; Strandberg TE; Faergeman O; Kastelein JJ; Olsson AG; Tikkanen MJ; Larsen ML; Lindahl C; Pedersen TR;
Atherosclerosis; 2009 Aug; 205(2):522-7. PubMed ID: 19327776
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein A-II is inversely associated with risk of future coronary artery disease.
Birjmohun RS; Dallinga-Thie GM; Kuivenhoven JA; Stroes ES; Otvos JD; Wareham NJ; Luben R; Kastelein JJ; Khaw KT; Boekholdt SM
Circulation; 2007 Oct; 116(18):2029-35. PubMed ID: 17923573
[TBL] [Abstract][Full Text] [Related]
9. apoB/apoA-I Ratio and Lp(a) Associations With Aortic Valve Stenosis Incidence: Insights From the EPIC-Norfolk Prospective Population Study.
Zheng KH; Arsenault BJ; Kaiser Y; Khaw KT; Wareham NJ; Stroes ESG; Boekholdt SM
J Am Heart Assoc; 2019 Aug; 8(16):e013020. PubMed ID: 31407609
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial.
Nicholls SJ; Gordon A; Johansson J; Wolski K; Ballantyne CM; Kastelein JJ; Taylor A; Borgman M; Nissen SE
J Am Coll Cardiol; 2011 Mar; 57(9):1111-9. PubMed ID: 21255957
[TBL] [Abstract][Full Text] [Related]
11. Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL).
Holme I; Cater NB; Faergeman O; Kastelein JJ; Olsson AG; Tikkanen MJ; Larsen ML; Lindahl C; Pedersen TR;
Ann Med; 2008; 40(6):456-64. PubMed ID: 19160529
[TBL] [Abstract][Full Text] [Related]
12. Common variation in cholesteryl ester transfer protein: relationship of first major adverse cardiovascular events with the apolipoprotein B/apolipoprotein A-I ratio and the total cholesterol/high-density lipoprotein cholesterol ratio.
Kappelle PJ; Gansevoort RT; Hillege HJ; Wolffenbuttel BH; Dullaart RP;
J Clin Lipidol; 2013; 7(1):56-64. PubMed ID: 23351584
[TBL] [Abstract][Full Text] [Related]
13. Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk.
van der Steeg WA; Boekholdt SM; Stein EA; El-Harchaoui K; Stroes ES; Sandhu MS; Wareham NJ; Jukema JW; Luben R; Zwinderman AH; Kastelein JJ; Khaw KT
Ann Intern Med; 2007 May; 146(9):640-8. PubMed ID: 17470832
[TBL] [Abstract][Full Text] [Related]
14. Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study.
van Capelleveen JC; Lee SR; Verbeek R; Kastelein JJP; Wareham NJ; Stroes ESG; Hovingh GK; Khaw KT; Boekholdt SM; Witztum JL; Tsimikas S
J Clin Lipidol; 2018; 12(6):1493-1501.e11. PubMed ID: 30249512
[TBL] [Abstract][Full Text] [Related]
15. Age and Cardiovascular Risk Attributable to Apolipoprotein B, Low-Density Lipoprotein Cholesterol or Non-High-Density Lipoprotein Cholesterol.
Sniderman AD; Islam S; McQueen M; Pencina M; Furberg CD; Thanassoulis G; Yusuf S
J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27737874
[TBL] [Abstract][Full Text] [Related]
16. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk.
Walldius G; Jungner I; Aastveit AH; Holme I; Furberg CD; Sniderman AD
Clin Chem Lab Med; 2004; 42(12):1355-63. PubMed ID: 15576296
[TBL] [Abstract][Full Text] [Related]
17. ApoB/A1 and LDL-C/HDL-C and the prediction of cardiovascular risk in statin-treated patients.
Liem AH; van de Woestijne AP; Roeters van Lennep HW; Zwinderman AH; van der Steeg WA; Jukema JW
Curr Med Res Opin; 2008 Feb; 24(2):359-64. PubMed ID: 18081989
[TBL] [Abstract][Full Text] [Related]
18. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes).
Albers JJ; Slee A; O'Brien KD; Robinson JG; Kashyap ML; Kwiterovich PO; Xu P; Marcovina SM
J Am Coll Cardiol; 2013 Oct; 62(17):1575-9. PubMed ID: 23973688
[TBL] [Abstract][Full Text] [Related]
19. The ratio of HDL-C to apoA-I interacts with free triiodothyronine to modulate coronary artery disease risk.
Li L; Cai G; Lu W; Li F; Yu L; Xiao J
BMC Cardiovasc Disord; 2021 Oct; 21(1):504. PubMed ID: 34666674
[TBL] [Abstract][Full Text] [Related]
20. Association between paraoxonase-1 activity and lipid peroxidation indicator levels in people living in the Antalya region with angiographically documented coronary artery disease.
Göçmen AY; Gümüşlü S; Semiz E
Clin Cardiol; 2004 Jul; 27(7):426-30. PubMed ID: 15298047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
